Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01377610 · ClinicalTrials.gov registry record · Phase 1
Improved Strategies for Outpatient Opioid Detoxification
A Phase 1 study of Opioid Dependence, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT01377610: Completed Phase 1 study of Opioid Dependence, sponsored by New York State Psychiatric Institute.
NCT01377610 is a Phase 1 study of Opioid Dependence that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 150 participants, roughly in line with the 153-participant average among 29 other Opioid Dependence trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01377610, a Phase 1 study of Opioid Dependence, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will randomize 210 opioid-dependent participants to one of two outpatient detoxification strategies: (1) a standard 7-day buprenorphine induction and gradual taper from 8 mg to 0 mg vs. (2) 7-day oral naltrexone induction; both groups will receive a single administration of a Vivitrol injection: at Day 8 for the naltrexone induction group and Day 15 for the buprenorphine group. The naltrexone arm is a modification of our current inpatient naltrexone induction procedure, consisting of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses, prior to administering a dose of injectable naltrexone on Day 8. All participants will receive an intensive behavioral therapy for five weeks and will be followed for the subsequent 8 weeks to assess the longer-term outcome of the initial treatment. The primary outcome will be percentage of patients in each group successfully inducted onto Vivitrol. Key secondary outcomes will be 2-week abstinence at Weeks 4-5 (3rd and 4th weeks after Vivitrol injection), rates of completion of the 8-day detoxification, and percentage of patients in each group who return for additional Vivitrol injections in post-study follow-up. The main goal of this Stage 1a pilot study is to develop an improved outpatient opioid detoxification strategy, with particular relevance to newly diagnosed heroin addicts and prescription opioid abusers not seeking long-term agonist maintenance. Specific Aim #1: To develop procedures for outpatient opioid detoxification which include naltrexone to facilitate detoxification. Specific Aim #2: To compare injectable naltrexone induction rates between the naltrexone and buprenorphine groups following short-term outpatient opioid detoxification approach for initiating treatment for opioid dependence.
Primary Outcome
Comparison of the percentage of patients assigned to each detoxification group (oral naltrexone vs. buprenorphine) who receive Vivitrol at the completion of detoxification.
Conditions Studied
Interventions
- DRUG Buprenorphine
- DRUG oral naltrexone
- DRUG Vivitrol
Study Locations (1)
New York
- Substance Treatment and Research Service (STARS), Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2011-06 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
What the finished NCT01377610 record still lists
NCT01377610 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 153-participant average among 29 other Opioid Dependence trials with a reported enrollment target.
The record links to 1 condition, with Opioid Dependence appearing as the primary indexed condition, and to 3 interventions - of which Buprenorphine is the first listed.
NCT01377610 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01377610 about?
NCT01377610 is a clinical study titled "Improved Strategies for Outpatient Opioid Detoxification". The investigators will randomize 210 opioid-dependent participants to one of two outpatient detoxification strategies: (1) a standard 7-day buprenorphine induction and gradual taper from 8 mg to 0 mg vs. (2) 7-day oral naltrexone induction; both groups will receive a single administration of a Vivit...
What is the current status of trial NCT01377610?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2011-06. Estimated completion is 2017-12.
What conditions does trial NCT01377610 study?
This clinical trial studies the following conditions: Opioid Dependence.
What interventions are being tested in trial NCT01377610?
The interventions under investigation include: Buprenorphine (DRUG), oral naltrexone (DRUG), Vivitrol (DRUG).
Who is sponsoring clinical trial NCT01377610?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01377610 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01377610's enrollment target sits among peer trials
150 10th of 29 higher than 20 of 29 other Opioid Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis
RECRUITING · Phase 1
-
Aprepitant Effects in Intravenous Heroin Dependence
COMPLETED · Phase 1
-
Remote Observed Dosing of Suboxone to Improve Clinical Practice
COMPLETED · Phase 1
-
Medication-Assisted Treatment for Youth With Substance Use Disorders
COMPLETED · Phase 1
-
Medications Development for Drug Abuse Disorders
COMPLETED · Phase 1
-
Neuromodulation and Cognitive Training in Opioid Use Disorder
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia